English
SGM-101 could provide a new approach for patients diagnosed with CRC, most of whom undergo surgery.
Montpellier, France, 17 octobre 2019 – SurgiMab today announces that the first US patient has been recruited in its pivotal Phase 3 clinical trial of SGM-101, in a patient with colorectal cancer (CRC).
The randomized Phase 3 trial, shall enroll 300 CRC patients in ten clinical centers in the US and in Europe.
The trial will assess the clinical benefit of using SGM-101 as the intraoperative imaging agent in Fluorescence-Guided Surgery procedures, to identify cancer lesions in real-time. Participating patients will receive 10mg of SGM-101 four days prior to the scheduled CRC surgery. Preliminary clinical data of the Phase 3 trial is expected in 2020.